Eintrag weiter verarbeiten
Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vi...
Gespeichert in:
| Veröffentlicht in: | Circulation 135(2017), 10, Seite 1001-1003 |
|---|---|
| Personen und Körperschaften: | , |
| Titel: | Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis/ Samuel M. Lindner, Christopher B. Fordyce, Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Günter Breithardt, Kenneth W. Mahaffey, Daniel E. Singer, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Scott D. Berkowitz, Christopher C. Nessel, Richard C. Becker, Keith A.A. Fox, Manesh R. Patel and on behalf of the ROCKET AF Steering Committee and Investigators |
| Format: | E-Book-Kapitel |
| Sprache: | Englisch |
| veröffentlicht: |
March 6, 2017
|
| Gesamtaufnahme: |
: Circulation, 135(2017), 10, Seite 1001-1003
, volume:135 |
| Quelle: | Verbunddaten SWB Lizenzfreie Online-Ressourcen |
| LEADER | 02354caa a2200457 4500 | ||
|---|---|---|---|
| 001 | 0-1556595875 | ||
| 003 | DE-627 | ||
| 005 | 20220813160857.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170413s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCULATIONAHA.116.024666 |2 doi | |
| 035 | |a (DE-627)1556595875 | ||
| 035 | |a (DE-576)486595870 | ||
| 035 | |a (DE-599)BSZ486595870 | ||
| 035 | |a (OCoLC)1340972795 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lindner, Samuel M. |e VerfasserIn |0 (DE-588)1129883914 |0 (DE-627)884486044 |0 (DE-576)486597369 |4 aut | |
| 245 | 1 | 0 | |a Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin |b A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis |c Samuel M. Lindner, Christopher B. Fordyce, Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Günter Breithardt, Kenneth W. Mahaffey, Daniel E. Singer, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Scott D. Berkowitz, Christopher C. Nessel, Richard C. Becker, Keith A.A. Fox, Manesh R. Patel and on behalf of the ROCKET AF Steering Committee and Investigators |
| 264 | 1 | |c March 6, 2017 | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am: 13.04.2017 | ||
| 700 | 1 | |a Hacke, Werner |d 1948- |e VerfasserIn |0 (DE-588)12021699X |0 (DE-627)080530346 |0 (DE-576)164358854 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation |d Philadelphia, Pa. : Lippincott, Williams & Wilkins, 1950 |g 135(2017), 10, Seite 1001-1003 |h Online-Ressource |w (DE-627)265784670 |w (DE-600)1466401-X |w (DE-576)074891189 |x 1524-4539 |7 nnns |
| 773 | 1 | 8 | |g volume:135 |g year:2017 |g number:10 |g pages:1001-1003 |g extent:3 |
| 856 | 4 | 0 | |u https://doi.org/10.1161/CIRCULATIONAHA.116.024666 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 936 | u | w | |d 135 |j 2017 |e 10 |h 1001-1003 |g 3 |
| 951 | |a AR | ||
| 856 | 4 | 0 | |u https://doi.org/10.1161/CIRCULATIONAHA.116.024666 |9 LFER |
| 852 | |a LFER |z 2018-03-07T00:00:00Z | ||
| 970 | |c OD | ||
| 971 | |c EBOOK | ||
| 972 | |c EBOOK | ||
| 973 | |c Aufsatz | ||
| 935 | |a lfer | ||
| 900 | |a Hacke, W. | ||
| 951 | |b XD-US | ||
| 980 | |a 1556595875 |b 0 |k 1556595875 |o 486595870 |c lfer | ||
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Treatment+consistency+across+levels+of+baseline+renal+function+with+Rivaroxaban+or+Warfarin%3A+A+ROCKET+AF+%28Rivaroxaban+once-daily%2C+oral%2C+direct+factor+Xa+inhibition+compared+with+vitamin+k+antagonism+for+prevention+of+stroke+and+embolism+trial+in+atrial+fibrillation%29+analysis&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rft.creator=Lindner%2C+Samuel+M.&rft.pub=&rft.format=Journal&rft.language=English&rft.issn=1524-4539 |
|---|
| _version_ | 1757948297121628160 |
|---|---|
| access_facet | Electronic Resources |
| author | Lindner, Samuel M., Hacke, Werner |
| author_facet | Lindner, Samuel M., Hacke, Werner |
| author_role | aut, aut |
| author_sort | Lindner, Samuel M. |
| author_variant | s m l sm sml, w h wh |
| callnumber-sort | |
| collection | lfer |
| container_reference | 135(2017), 10, Seite 1001-1003 |
| container_title | Circulation |
| ctrlnum | (DE-627)1556595875, (DE-576)486595870, (DE-599)BSZ486595870, (OCoLC)1340972795 |
| doi_str_mv | 10.1161/CIRCULATIONAHA.116.024666 |
| facet_avail | Online, Free |
| finc_class_facet | not assigned |
| finc_id_str | 0020973006 |
| footnote | Gesehen am: 13.04.2017 |
| format | ElectronicBookComponentPart |
| format_access_txtF_mv | Article, E-Article |
| format_de105 | Ebook |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_del152 | Buch |
| format_detail_txtF_mv | text-online-monograph-child |
| format_dezi4 | e-Book |
| format_finc | Article, E-Article |
| format_legacy | ElectronicBookPart |
| format_strict_txtF_mv | E-Article |
| geogr_code | not assigned |
| geogr_code_person | USA |
| hierarchy_parent_id | 0-265784670 |
| hierarchy_parent_title | Circulation |
| hierarchy_sequence | 135(2017), 10, Seite 1001-1003 |
| hierarchy_top_id | 0-265784670 |
| hierarchy_top_title | Circulation |
| id | 0-1556595875 |
| illustrated | Not Illustrated |
| imprint | March 6, 2017 |
| imprint_str_mv | March 6, 2017 |
| institution | DE-D117, DE-105, LFER, DE-Ch1, DE-15, DE-14, DE-Zwi2 |
| is_hierarchy_id | 0-1556595875 |
| is_hierarchy_title | Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis |
| isil_str_mv | LFER |
| issn | 1524-4539 |
| kxp_id_str | 1556595875 |
| language | English |
| last_indexed | 2023-02-16T01:15:39.707Z |
| marc024a_ct_mv | 10.1161/CIRCULATIONAHA.116.024666 |
| match_str | lindner2017treatmentconsistencyacrosslevelsofbaselinerenalfunctionwithrivaroxabanorwarfarinarocketafrivaroxabanoncedailyoraldirectfactorxainhibitioncomparedwithvitaminkantagonismforpreventionofstrokeandembolismtrialinatrialfibrillationanalysis |
| mega_collection | Verbunddaten SWB, Lizenzfreie Online-Ressourcen |
| misc_de105 | EBOOK |
| multipart_link | 074891189 |
| multipart_part | (074891189)135(2017), 10, Seite 1001-1003 |
| names_id_str_mv | (DE-588)1129883914, (DE-627)884486044, (DE-576)486597369, (DE-588)12021699X, (DE-627)080530346, (DE-576)164358854 |
| oclc_num | 1340972795 |
| physical | 3 |
| publishDate | March 6, 2017 |
| publishDateSort | 2017 |
| publishPlace | |
| publisher | |
| record_format | marcfinc |
| record_id | 486595870 |
| recordtype | marcfinc |
| rvk_facet | No subject assigned |
| source_id | 0 |
| spelling | Lindner, Samuel M. VerfasserIn (DE-588)1129883914 (DE-627)884486044 (DE-576)486597369 aut, Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis Samuel M. Lindner, Christopher B. Fordyce, Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Günter Breithardt, Kenneth W. Mahaffey, Daniel E. Singer, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Scott D. Berkowitz, Christopher C. Nessel, Richard C. Becker, Keith A.A. Fox, Manesh R. Patel and on behalf of the ROCKET AF Steering Committee and Investigators, March 6, 2017, 3, Text txt rdacontent, Computermedien c rdamedia, Online-Ressource cr rdacarrier, Gesehen am: 13.04.2017, Hacke, Werner 1948- VerfasserIn (DE-588)12021699X (DE-627)080530346 (DE-576)164358854 aut, Enthalten in Circulation Philadelphia, Pa. : Lippincott, Williams & Wilkins, 1950 135(2017), 10, Seite 1001-1003 Online-Ressource (DE-627)265784670 (DE-600)1466401-X (DE-576)074891189 1524-4539 nnns, volume:135 year:2017 number:10 pages:1001-1003 extent:3, https://doi.org/10.1161/CIRCULATIONAHA.116.024666 Verlag Resolving-System kostenfrei Volltext, https://doi.org/10.1161/CIRCULATIONAHA.116.024666 LFER, LFER 2018-03-07T00:00:00Z |
| spellingShingle | Lindner, Samuel M., Hacke, Werner, Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis |
| swb_id_str | 486595870 |
| title | Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis |
| title_auth | Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis |
| title_full | Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis Samuel M. Lindner, Christopher B. Fordyce, Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Günter Breithardt, Kenneth W. Mahaffey, Daniel E. Singer, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Scott D. Berkowitz, Christopher C. Nessel, Richard C. Becker, Keith A.A. Fox, Manesh R. Patel and on behalf of the ROCKET AF Steering Committee and Investigators |
| title_fullStr | Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis Samuel M. Lindner, Christopher B. Fordyce, Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Günter Breithardt, Kenneth W. Mahaffey, Daniel E. Singer, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Scott D. Berkowitz, Christopher C. Nessel, Richard C. Becker, Keith A.A. Fox, Manesh R. Patel and on behalf of the ROCKET AF Steering Committee and Investigators |
| title_full_unstemmed | Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis Samuel M. Lindner, Christopher B. Fordyce, Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Günter Breithardt, Kenneth W. Mahaffey, Daniel E. Singer, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Scott D. Berkowitz, Christopher C. Nessel, Richard C. Becker, Keith A.A. Fox, Manesh R. Patel and on behalf of the ROCKET AF Steering Committee and Investigators |
| title_in_hierarchy | Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis / Samuel M. Lindner, Christopher B. Fordyce, Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Günter Breithardt, Kenneth W. Mahaffey, Daniel E. Singer, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Scott D. Berkowitz, Christopher C. Nessel, Richard C. Becker, Keith A.A. Fox, Manesh R. Patel and on behalf of the ROCKET AF Steering Committee and Investigators, |
| title_short | Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin |
| title_sort | treatment consistency across levels of baseline renal function with rivaroxaban or warfarin a rocket af rivaroxaban once daily oral direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation analysis |
| title_sub | A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis |
| url | https://doi.org/10.1161/CIRCULATIONAHA.116.024666 |